vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Verastem, Inc. (VSTM). Click either name above to swap in a different company.
Verastem, Inc. is the larger business by last-quarter revenue ($11.2M vs $10.7M, roughly 1.0× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -876.3%, a 899.8% gap on every dollar of revenue.
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
ABUS vs VSTM — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $11.2M |
| Net Profit | $2.5M | $-98.5M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | -362.2% |
| Net Margin | 23.5% | -876.3% |
| Revenue YoY | 522.2% | — |
| Net Profit YoY | 112.7% | -311.1% |
| EPS (diluted) | $0.01 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $11.2M | ||
| Q2 25 | $10.7M | $2.1M | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $10.0M | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $4.7M | — | ||
| Q2 23 | $4.7M | — | ||
| Q1 23 | $6.7M | — |
| Q3 25 | — | $-98.5M | ||
| Q2 25 | $2.5M | $-25.9M | ||
| Q3 24 | — | $-24.0M | ||
| Q2 24 | — | $-8.3M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-20.1M | — | ||
| Q2 23 | $-17.1M | — | ||
| Q1 23 | $-16.3M | — |
| Q3 25 | — | -362.2% | ||
| Q2 25 | 13.9% | -2047.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -182.8% | ||
| Q4 23 | -967.2% | — | ||
| Q3 23 | -462.8% | — | ||
| Q2 23 | -395.3% | — | ||
| Q1 23 | -260.4% | — |
| Q3 25 | — | -876.3% | ||
| Q2 25 | 23.5% | -1213.6% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -82.6% | ||
| Q4 23 | — | — | ||
| Q3 23 | -431.6% | — | ||
| Q2 23 | -367.5% | — | ||
| Q1 23 | -244.3% | — |
| Q3 25 | — | $-1.35 | ||
| Q2 25 | $0.01 | $-0.62 | ||
| Q3 24 | — | $-0.60 | ||
| Q2 24 | — | $-0.31 | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | — | ||
| Q2 23 | $-0.10 | — | ||
| Q1 23 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $137.7M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $-15.5M |
| Total Assets | $103.3M | $176.9M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $137.7M | ||
| Q2 25 | $37.4M | $164.3M | ||
| Q3 24 | — | $113.2M | ||
| Q2 24 | — | $83.4M | ||
| Q4 23 | $126.0M | — | ||
| Q3 23 | $17.5M | — | ||
| Q2 23 | $27.2M | — | ||
| Q1 23 | $40.6M | — |
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q3 24 | — | $40.5M | ||
| Q2 24 | — | $40.3M | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — | ||
| Q1 23 | $0 | — |
| Q3 25 | — | $-15.5M | ||
| Q2 25 | $83.0M | $36.1M | ||
| Q3 24 | — | $11.1M | ||
| Q2 24 | — | $18.9M | ||
| Q4 23 | $106.0M | — | ||
| Q3 23 | $119.3M | — | ||
| Q2 23 | $134.7M | — | ||
| Q1 23 | $143.9M | — |
| Q3 25 | — | $176.9M | ||
| Q2 25 | $103.3M | $196.3M | ||
| Q3 24 | — | $126.4M | ||
| Q2 24 | — | $105.7M | ||
| Q4 23 | $144.4M | — | ||
| Q3 23 | $158.6M | — | ||
| Q2 23 | $176.8M | — | ||
| Q1 23 | $191.2M | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q3 24 | — | 3.66× | ||
| Q2 24 | — | 2.14× | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | — | ||
| Q2 23 | 0.00× | — | ||
| Q1 23 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-36.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-36.2M | ||
| Q2 25 | $-15.7M | $-32.7M | ||
| Q3 24 | — | $-23.8M | ||
| Q2 24 | — | $-27.6M | ||
| Q4 23 | $-17.3M | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-19.6M | — | ||
| Q1 23 | $-27.3M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-27.6M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-20.4M | — | ||
| Q1 23 | $-27.4M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -275.8% | ||
| Q4 23 | — | — | ||
| Q3 23 | -468.4% | — | ||
| Q2 23 | -439.0% | — | ||
| Q1 23 | -410.0% | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.7% | — | ||
| Q2 23 | 18.5% | — | ||
| Q1 23 | 1.7% | — |
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
